Abstract

The emergence of new viral infections, such as COVID-19, Ebola, and Zika, has underscored the importance of effective antiviral treatments. However, the development of antiviral drug resistance presents a formidable challenge to managing these emerging infections. This article examines the intricate interplay between antiviral drug resistance and emerging viral infections. It delves into the factors contributing to resistance development, the susceptibility of emerging infections to resistance, and strategies to mitigate this phenomenon. By exploring the multifaceted nature of antiviral drug resistance in the context of emerging viral threats, this article highlights the urgent need for comprehensive approaches to ensure the continued efficacy of antiviral therapies.